Scott Alan Samuels Acquires 15,000 Shares of Geron Co. (NASDAQ:GERN) Stock

Geron Co. (NASDAQ:GERN) EVP Scott Alan Samuels purchased 15,000 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were purchased at an average cost of $1.61 per share, with a total value of $24,150.00. Following the acquisition, the executive vice president now owns 26,682 shares in the company, valued at $42,958.02. This trade represents a 128.40 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Geron Trading Down 2.8 %

Shares of NASDAQ GERN opened at $1.71 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron Co. has a 52-week low of $1.46 and a 52-week high of $5.34. The firm has a 50 day moving average price of $2.93 and a two-hundred day moving average price of $3.76. The stock has a market cap of $1.03 billion, a P/E ratio of -5.34 and a beta of 0.53.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million during the quarter, compared to analysts’ expectations of $45.29 million. As a group, equities analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Needham & Company LLC cut their price target on shares of Geron from $7.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Stifel Nicolaus cut their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Barclays reaffirmed an “overweight” rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a report on Thursday. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price target for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Finally, Scotiabank cut their price target on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Institutional Investors Weigh In On Geron

Several large investors have recently modified their holdings of GERN. Creative Planning increased its position in shares of Geron by 23.8% during the third quarter. Creative Planning now owns 92,784 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 17,837 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Geron by 23.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,094 shares during the period. abrdn plc acquired a new stake in shares of Geron during the third quarter worth $6,752,000. US Bancorp DE increased its position in shares of Geron by 68.4% during the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 7,429 shares during the period. Finally, Rovin Capital UT ADV acquired a new stake in Geron in the third quarter worth $62,000. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.